MX350145B - Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo. - Google Patents

Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.

Info

Publication number
MX350145B
MX350145B MX2014000748A MX2014000748A MX350145B MX 350145 B MX350145 B MX 350145B MX 2014000748 A MX2014000748 A MX 2014000748A MX 2014000748 A MX2014000748 A MX 2014000748A MX 350145 B MX350145 B MX 350145B
Authority
MX
Mexico
Prior art keywords
bromelain
treatment
connective tissue
proteolytic extract
tissue disorders
Prior art date
Application number
MX2014000748A
Other languages
English (en)
Other versions
MX2014000748A (es
Inventor
Lior Rosenberg
Guy Rubin
Eilon Asculai
Original Assignee
Mediwound Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mediwound Ltd filed Critical Mediwound Ltd
Publication of MX2014000748A publication Critical patent/MX2014000748A/es
Publication of MX350145B publication Critical patent/MX350145B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1732—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22031—Ananain (3.4.22.31)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22032—Stem bromelain (3.4.22.32)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)

Abstract

La presente invención se refiere a un extracto proteolítico obtenido a partir de bromelaína para el tratamiento de enfermedades del tejido conectivo; en particular, la presente invención se relaciona con una composición farmacéutica que comprende un extracto proteolitico obtenido a partir de bromelaína para el tratamiento de enfermedades tale como la enfermedad de Dupuytren y enfermedad de Peyronie. El uso de una composición farmacéutica que comprende un extracto proteolítico para la preparación de un medicamento para tratar una enfermedad del tejido conectivo, en donde el extracto proteolítico comprende la proteasa de cisteína del tallo de bromelaína EC3.4.22.32 y ananaína EC 3.4.22.31, y una lectina similar a jabalina, en donde la enfermedad del tejido conectivo está asociada con deposición en exceso de colágeno.
MX2014000748A 2011-07-20 2012-07-19 Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo. MX350145B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161509612P 2011-07-20 2011-07-20
PCT/IL2012/050261 WO2013011514A1 (en) 2011-07-20 2012-07-19 Proteolytic extract from bromelain for the treatment of connective tissue disorders

Publications (2)

Publication Number Publication Date
MX2014000748A MX2014000748A (es) 2014-10-15
MX350145B true MX350145B (es) 2017-08-28

Family

ID=47557739

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000748A MX350145B (es) 2011-07-20 2012-07-19 Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.

Country Status (17)

Country Link
US (2) US9511126B2 (es)
EP (1) EP2734216B1 (es)
JP (1) JP6049714B2 (es)
KR (1) KR101921363B1 (es)
CN (1) CN103687607B (es)
AU (1) AU2012285378B2 (es)
BR (1) BR112014001439B1 (es)
CA (1) CA2842291C (es)
DK (1) DK2734216T3 (es)
ES (1) ES2690568T3 (es)
HU (1) HUE039689T2 (es)
MX (1) MX350145B (es)
PL (1) PL2734216T3 (es)
PT (1) PT2734216T (es)
RU (1) RU2625726C2 (es)
WO (1) WO2013011514A1 (es)
ZA (1) ZA201400946B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3210619A2 (en) * 2014-10-24 2017-08-30 HPRD-Health Products Research and Development LDA Topical formulation for treating skin or mucosal infections, preparation method and uses thereof
WO2017130204A1 (en) * 2016-01-31 2017-08-03 Mediwound Ltd. Debriding composition for treating wounds
US20190142910A1 (en) * 2016-04-18 2019-05-16 Mediwound Ltd Methods of debridement of chronic wounds
KR101800788B1 (ko) * 2017-03-31 2017-11-27 박영오 켈로이드 흉터 개선용 화장료 조성물

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197291A (en) 1974-01-08 1980-04-08 Gerold K. V. Klein Hydrolytic enzyme material
GB8724728D0 (en) * 1987-10-22 1987-11-25 Genzyme Corp Cysteine proteinase
DE69019141T2 (de) 1989-01-27 1996-01-18 Immunolytics Inc Zusammensetzung und verfahren für die behandlung gutartiger prostata-hypertrophie.
IL103969A (en) 1991-12-03 1997-01-10 Gerold K V Klein Proteolytic mixture containing escharase and method of isolating same
US5589171A (en) 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
US6086872A (en) 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
US6031005A (en) 1998-08-03 2000-02-29 Easterling; W. Jerry Composition and method for treating Peyronie's disease and related connective tissue disorders
US6022539A (en) 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
WO2002074329A1 (en) 2001-03-19 2002-09-26 Ribeiro Santana Cristiano Albe Pharmaceutical composition applied to the treatment of the peyronie disease and corresponding obtention process
US20030026794A1 (en) * 2001-07-31 2003-02-06 Howard Fein Selective enzyme treatment of skin conditions
WO2004037183A2 (en) 2002-10-22 2004-05-06 Harbor-Ucla Research And Education Institute Phosphodiester inhibitors and nitric oxide modulators for treating peyronie’s disease, arteriosclerosis and other fibrotic diseases
WO2005000331A2 (en) * 2003-06-04 2005-01-06 Mucosal Therapeutics, Inc. Compositions for the treatment and prevention of degenerative joint disorders
JP2007519756A (ja) * 2004-01-30 2007-07-19 アンジオテック インターナショナル アーゲー 拘縮を治療するための組成物および方法
IL165334A0 (en) 2004-11-22 2006-01-15 Mediwound Ltd Debriding composition from bromelain and methods of producing same
ITPD20050207A1 (it) 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
US7811560B2 (en) 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
BRPI0801929A2 (pt) * 2008-05-13 2010-01-12 Santana Cristiano Alberto Ribeiro processo e composição farmacêutica compreendendo enzimas proteolìticas vegetais em nanopartìculas supramoleculares, para tratamento da doença de peyronie, colagenoses e patologias fibróticas e uso

Also Published As

Publication number Publication date
US10293033B2 (en) 2019-05-21
DK2734216T3 (en) 2018-11-19
US20140154229A1 (en) 2014-06-05
BR112014001439A2 (pt) 2017-07-18
CA2842291A1 (en) 2013-01-24
AU2012285378B2 (en) 2017-03-02
CA2842291C (en) 2020-09-15
EP2734216A1 (en) 2014-05-28
PT2734216T (pt) 2018-11-07
EP2734216B1 (en) 2018-07-25
HUE039689T2 (hu) 2019-01-28
RU2625726C2 (ru) 2017-07-18
ES2690568T3 (es) 2018-11-21
CN103687607B (zh) 2018-01-30
US20170049865A1 (en) 2017-02-23
PL2734216T3 (pl) 2018-12-31
KR101921363B1 (ko) 2018-11-22
US9511126B2 (en) 2016-12-06
KR20140079757A (ko) 2014-06-27
JP2014520881A (ja) 2014-08-25
RU2014106299A (ru) 2015-08-27
MX2014000748A (es) 2014-10-15
CN103687607A (zh) 2014-03-26
JP6049714B2 (ja) 2016-12-21
ZA201400946B (en) 2015-11-25
EP2734216A4 (en) 2015-03-11
BR112014001439B1 (pt) 2021-05-25
WO2013011514A1 (en) 2013-01-24
AU2012285378A1 (en) 2014-01-23

Similar Documents

Publication Publication Date Title
WO2012080729A3 (en) Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies
BR112015005117A2 (pt) métodos de tratamento da doença de alzheimer e suas composições farmacêuticas
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
JO3776B1 (ar) التركيبات الصيدلانية لمثبط CDK4 / 6 ومثبط B-Raf
EA201200686A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера
MY198422A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
AU2012253759A8 (en) Tricyclic sulfonamide compounds and methods of making and using same
EA201270824A1 (ru) Соединения для уменьшения продукции бета-амилоида
WO2012170899A3 (en) Pharmaceutical compositions containing proteases and methods for the treatment of lysosomal storage diseases
EA201490004A1 (ru) Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей
BR112014008789A2 (pt) prevenção e tratamento de condições oculares
WO2010083239A3 (en) Therapeutic modulation of vaginal epithelium boundary lubrication
MX2012011776A (es) Nuevos compuestos para tratamiento de enfermedades asociadas con proteinas amiloides o tipo amiloide.
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
EA201300471A1 (ru) Замещенные 6-аминоникотинамиды в качестве модуляторов kcnq2/3
EP3653205A3 (en) Oxymethazoline for topical ophthalmic administration and uses thereof
EP2257161A4 (en) AHCY HYDROLASE INHIBITORS FOR THE TREATMENT OF HYPER-HOMOCYSEINEMIA
MX2013001842A (es) Composiciones de plasma rico en plaquetas.
BR112014011744A2 (pt) formulação de ação sustentável da forma 2 de ciclosporina
MX2011008261A (es) FORMULACIONES FARMACEUTICAS DE PEPTIDOS INHIBIDORES DE TGF-ß1.
WO2009136997A3 (en) Inhibitors of human cathepsin l, cathepsin b, and cathepsin s
MX350145B (es) Extracto proteolitico a partir de bromelaina para el tratamiento de trastornos del tejido conectivo.
EA201492271A1 (ru) Соединения хроманов

Legal Events

Date Code Title Description
FG Grant or registration